25D-NBOMe

25D-NBOMe, also known as NBOMe-2C-D and "divination", is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe, which is a potent agonist at the 5-HT_2A receptor. 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe. It was banned as a Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.

Use and effects

The dose range of 25D-NBOMe has been given as 0.3 to 1.2mg or more sublingually, with a typical dose estimate of 1.0mg.

Pharmacology

Pharmacodynamics

25D-NBOMe acts as an agonist of the serotonin 5-HT₂ receptors.
The drug produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.
25D-NBOMe has shown reinforcing effects in rodents. This included conditioned place preference and self-administration. Relatedly, the drug has been found to increase dopaminergic signaling in the nucleus accumbens.

History

25D-NBOMe was first described in the scientific literature by 2012.

Society and culture

Legal status

Canada

25D-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.

China

As of October 2015 25D-NBOMe is a controlled substance in China.

Finland

Scheduled in the "government decree on prohibited psychoactive substances in consumer markets".

Sweden

added 25D-NBOMe to schedule I as narcotics in Sweden as of Aug 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25D-NBOMe 2--N-etanamin.

United States

25D-NBOMe is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.